Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620945 | 1.00 | APP (0.43) | APPALDH1A1SNCA | |
| SCHEMBL16335431 | 0.89 | — | — | |
| SCHEMBL14330126 | 0.89 | — | — | |
| SCHEMBL13893498 | 0.77 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9244034 | 0.75 | APP (0.30) | APP | |
| SCHEMBL20647129 | 0.73 | APP (0.40) | APPSNCA | |
| SCHEMBL8411026 | 0.70 | APP (0.36) | APP | |
| SCHEMBL24595282 | 0.70 | TSHR (0.30) | — | |
| SCHEMBL9361086 | 0.70 | KDM4E (0.35) | APPALDH1A1 | |
| SCHEMBL9361093 | 0.70 | KDM4E (0.35) | APPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070320-A1 | ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS | WASHINGTON UNIVERSITY | 2019-03-07 | — | — | US | claimed |
| US-20160213792-A1 | HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-28 | — | — | US | claimed |
| EP-4024489-B1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC COMPONENTS | HELIATEK GMBH (DE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023126486-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | HELIATEK GMBH (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022144423-A1 | COMPOUND FOR AN OPTOELECTRONIC COMPONENT AND OPTOELECTRONIC COMPONENT CONTAINING THE COMPOUND | HELIATEK GMBH (DE) | 2022-07-07 | — | — | WO | disclosed |
| EP-3397637-B1 | COMPOUND FOR PHOTOACTIVE ORGANIC ELECTRONIC ELEMENT, AND PHOTOACTIVE ORGANIC ELECTRONIC ELEMENT COMPRISING THE COMPOUND | HELIATEK GMBH (DE) | 2021-08-11 | — | — | EP | disclosed |
| US-10335504-B2 | Heterocyclic molecules for biomedical imaging and therapeutic applications | WASHINGTON UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190070320-A1 | ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS | WASHINGTON UNIVERSITY | 2019-03-07 | — | — | US | disclosed |
| WO-2017114937-A1 | COMPOUND FOR PHOTOACTIVE ORGANIC ELECTRONIC COMPONENTS AND PHOTOACTIVE ORGANIC ELECTRONIC COMPONENT CONTAINING THE COMPOUND | HELIATEK GMBH (DE) | 2017-07-06 | — | — | WO | disclosed |
| EP-3187496-A1 | COMPOUND FOR PHOTOACTIVE ORGANIC ELECTRONIC DEVICES AND PHOTOACTIVE ORGANIC ELECTRONIC COMPONENT CONTAINING THE COMPOUND | Heliatek GmbH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-20160213792-A1 | HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-28 | — | — | US | disclosed |
| WO-2015051188-A1 | HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS | WASHINGTON UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335504-B2 | Heterocyclic molecules for biomedical imaging and therapeutic applications | APP, PSEN1, BACE1 | APP 1/4885ALDH1A1 2007/4885SNCA 124/4885 |
| US-20190070320-A1 | ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS | TARDBP, GRN, FUS | APP 101/4885ALDH1A1 4277/4885SNCA 17/4885 |
| US-20160213792-A1 | HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS | APP, PSEN1, BACE1 | APP 1/4885ALDH1A1 2007/4885SNCA 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.